Sodium–glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice

• DOI: 10.1111/jdi.13502
• Publication Date: 2021-01-13T23:29:08Z
• Authors: Taro Hirai; Munehiro Kitada; Itaru Monno; Erina Oda; Yoshihiro Hayashi; Keiji Shimada; Yuta Takagaki; Yoshio Ogura; Mizue Fujii; Kazunori Konishi; Masaru Sakurai; Atsushi Nakagawa; Daisuke Koya
• Keywords: Albuminuria

Abstract Aims/Introduction The aim of this study was to elucidate whether sodium–glucose cotransporter 2 inhibitors (SGLT2is) treatment has any renoprotective effect for type diabetes mellitus patients with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m in clinical practice. Materials and Methods We evaluated the annual eGFR slope 85 renal impairment, treated SGLT2is ≥2 years. Each patient's at start therapy. calculation change each patient obtained by acquired data before after years initial administration, followed analysis changes mean slope. Results participants' age 72.0 ± 9.4 years, 47.1 9.7 additional SGLT2is. administration (−0.11 0.20 /year) significantly slower than (−2.93 0.59 /year; P < 0.0001). Additionally, slowed decline eGFR, independent levels both albuminuria therapy started. In groups who showed ≥3 1–3 , there a significant slowing therapy, compared ( 0.001, respectively). Conclusions slows observed function